Evidence map›Paper›PMID 36371450›Full record

ArticleScientific reports2022

Structure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5.

Khadidiatou Mangou, Adam J Moore, Laty Gaye Thiam, Aboubacar Ba, Alessandra Orfanó, Ife Desamours, Duncan Ndungu Ndegwa, Justin Goodwin, Yicheng Guo, Zizhang Sheng and 13 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 4 countries.

Khadidiatou Mangou *G4 - Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.
Adam J Moore *Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Laty Gaye Thiam *G4 - Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.
Aboubacar BaG4 - Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.
Alessandra OrfanóDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Ife DesamoursDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Duncan Ndungu NdegwaDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Justin GoodwinDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Yicheng GuoAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Zizhang ShengAaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Saurabh D PatelZuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA.
Fatoumata DialloG4 - Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.
Seynabou D SeneG4 - Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.
Mariama N PouyeG4 - Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.
Awa Thioub FayeG4 - Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.
Alassane ThiamG4 - Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.
Vanessa NunezDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Cheikh Tidiane DiagneMIVEGEC (Infectious Diseases and Vector: Ecology, Genetics, Evolution and Control), University of Montpelier, IRD, CNRS, Montpellier, France.
Bacary Djilocalisse SadioPôle Virologie, Institut Pasteur de Dakar, Dakar, Senegal.
Lawrence ShapiroZuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA.
Ousmane FayePôle Virologie, Institut Pasteur de Dakar, Dakar, Senegal.
Alassane Mbengue *G4 - Malaria Experimental Genetic Approaches & Vaccines, Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de Dakar, Dakar, Senegal.
Amy K Bei *Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA. amy.bei@yale.edu.
Institut Pasteur de Dakar · SNYale University · USAaron Diamond AIDS Research Center · USColumbia University · USCentre National de la Recherche Scientifique · FR

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
PREDOCTORAL TRAINING PROGRAM IN MICROBIAL PATHOGENESIST32AI007640 · NIAID · YALE UNIVERSITY · PI GOODMAN, ANDREW L · 2000 to 2022
$4.3M
Evaluating the Functional Impact of Genetic Diversity on Malaria Vaccine CandidatesR01AI168238 · NIAID · YALE UNIVERSITY · PI Amy Kristine Bei · 2022 to 2026
$3.5M
Employing genetic and genomic surveillance to reveal mechanisms of malaria parasite persistenceK01TW010496 · FIC · YALE UNIVERSITY · PI BEI, AMY KRISTINE · 2016 to 2021
$754k
FIC NIH HHS K01 TW010496NCATS NIH HHS UL1 TR001863NIAID NIH HHS R01 AI168238NIAID NIH HHS T32 AI007640NIH HHS R01 AI168238
6 · The paper itself

Abstract

The recent stall in the global reduction of malaria deaths has made the development of a highly effective vaccine essential. A major challenge to developing an efficacious vaccine is the extensive diversity of Plasmodium falciparum antigens. While genetic diversity plays a major role in immune evasion and is a barrier to the development of both natural and vaccine-induced protective immunity, it has been under-prioritized in the evaluation of malaria vaccine candidates. This study uses genomic approaches to evaluate genetic diversity in next generation malaria vaccine candidate PfRh5. We used targeted deep amplicon sequencing to identify non-synonymous Single Nucleotide Polymorphisms (SNPs) in PfRh5 (Reticulocyte-Binding Protein Homologue 5) in 189 P. falciparum positive samples from Southern Senegal and identified 74 novel SNPs. We evaluated the population prevalence of these SNPs as well as the frequency in individual samples and found that only a single SNP, C203Y, was present at every site. Many SNPs were unique to the individual sampled, with over 90% of SNPs being found in just one infected individual. In addition to population prevalence, we assessed individual level SNP frequencies which revealed that some SNPs were dominant (frequency of greater than 25% in a polygenomic sample) whereas most were rare, present at 2% or less of total reads mapped to the reference at the given position. Structural modeling uncovered 3 novel SNPs occurring under epitopes bound by inhibitory monoclonal antibodies, potentially impacting immune evasion, while other SNPs were predicted to impact PfRh5 structure or interactions with the receptor or binding partners. Our data demonstrate that PfRh5 exhibits greater genetic diversity than previously described, with the caveat that most of the uncovered SNPs are at a low overall frequency in the individual and prevalence in the population. The structural studies reveal that novel SNPs could have functional implications on PfRh5 receptor binding, complex formation, or immune evasion, supporting continued efforts to validate PfRh5 as an effective malaria vaccine target and development of a PfRh5 vaccine.

Indexed as

Malaria, FalciparumMalaria VaccinesAntibodies, ProtozoanAntigens, ProtozoanCarrier ProteinsHumansPlasmodium falciparumProtozoan ProteinsAntibodies, ProtozoanAntigens, ProtozoanCarrier ProteinsMalaria VaccinesProtozoan Proteins

Identifiers

PMID36371450
PMCPMC9653458
OpenAlexW4309074427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.